journal
Journals Annals of Oncology : Official ...

Annals of Oncology : Official Journal of the European Society for Medical Oncology

https://read.qxmd.com/read/38986770/elevating-cancer-on-the-global-health-agenda-towards-the-4th-high-level-meeting-on-ncds-2025
#1
EDITORIAL
Raffaella Casolino, Bente Mikkelsen, Andrè Ilbawi
No abstract text is available yet for this article.
July 8, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38986769/total-neoadjuvant-therapy-with-mfolfirinox-versus-preoperative-chemoradiotherapy-in-patients-with-locally-advanced-rectal-cancer-long-term-results-of-the-unicancer-prodige-23-trial
#2
JOURNAL ARTICLE
T Conroy, F Castan, P-L Etienne, E Rio, N Mesgouez-Nebout, L Evesque, V Vendrely, X Artignan, O Bouché, D Gargot, V Boige, N Bonichon-Lamichhane, C Louvet, C Morand, C de la Fouchardière, A Boilève, M Delaye, S Gourgou, V Pezzella, C Borg
BACKGROUND: The standard of care for the treatment of locally advanced rectal cancer results in an excellent local disease control but the metastasis rates remain high. PRODIGE 23 demonstrated improved disease-free and metastatic-free survival with total neoadjuvant therapy versus standard of care in this population. Long-term analysis of overall survival is reported here. PATIENTS AND METHODS: The study design, participants, and primary endpoint disease-free survival (DFS) have been reported for this multicenter, randomized, open-label, phase 3 trial investigating the neoadjuvant chemotherapy with mFOLFIRINOX (6 cycles) followed by chemoradiotherapy, surgery, and adjuvant chemotherapy (6 cycles), versus chemoradiotherapy, surgery, and adjuvant chemotherapy (12 cycles) in patients with locally advanced rectal adenocarcinoma under peritoneal reflection on MRI, and staged cT3/T4...
July 8, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38986768/population-based-germline-breast-cancer-gene-association-studies-and-meta-analysis-to-inform-wider-mainstream-testing
#3
JOURNAL ARTICLE
C F Rowlands, S Allen, J Balmaña, S M Domchek, D G Evans, H Hanson, N Hoogerbrugge, P A James, K Nathanson, M Robson, M Tischkowitz, W D Foulkes, C Turnbull
BACKGROUND: Germline genetic testing, previously restricted to familial and young-onset breast cancer, is now offered increasingly broadly to 'population-type' breast cancer patients in mainstream oncology clinics, with wide variation in the genes included. METHODS: Weighted meta-analysis was performed for three population-based case-control studies (BRIDGES, CARRIERS and UK Biobank) comprising in total 101,397 women with breast cancer and 312,944 women without breast cancer, to quantify for 37 putative breast cancer susceptibility genes (BCSGs) the frequency of pathogenic variants (PVs) in unselected, 'population-type' breast cancer cases and their association with breast cancer and its subtypes...
July 8, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38977064/neratinib-and-ado-trastuzumab-emtansine-for-pre-treated-and-untreated-her2-positive-breast-cancer-brain-metastases-translational-breast-cancer-research-consortium-trial-022
#4
JOURNAL ARTICLE
R A Freedman, H M Heiling, T Li, D Trapani, N Tayob, K L Smith, R Davis, A M Pereslete, M K DeMeo, C Cotter, W Y Chen, H A Parsons, C A Santa-Maria, C Van Poznak, B Moy, A M Brufsky, M E Melisko, C C O'Sullivan, N Ashai, Y Rauf, J R Nangia, R T Burns, J Savoie, A C Wolff, E P Winer, M F Rimawi, I E Krop, N U Lin
PURPOSE: Treatment options for HER2-positive breast cancer brain metastases (BCBM) remain limited. We previously reported central nervous system (CNS) activity for neratinib and neratinib-capecitabine. Preclinical data suggest that neratinib may overcome resistance to ado-trastuzumab-emtansine (T-DM1) when given in combination. In TBCRC 022's cohort 4, we examined the efficacy of neratinib plus T-DM1 in patients with HER2-positive BCBM. PATIENTS AND METHODS: In this multicenter, phase II study, patients with measurable HER2-positive BCBM received neratinib 160 mg daily plus T-DM1 3...
July 6, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38969010/primary-tumor-resection-for-asymptomatic-colorectal-cancer-with-unresectable-metastasis-the-end-of-the-dilemma
#5
EDITORIAL
Sebastiano Biondo, Ricardo Frago, Esther Kreisler
No abstract text is available yet for this article.
July 3, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38964714/neoadjuvant-short-course-radiotherapy-followed-by-camrelizumab-and-chemotherapy-in-locally-advanced-rectal-cancer-union-early-outcomes-of-a-multicenter-randomized-phase-iii-trial
#6
JOURNAL ARTICLE
Z Y Lin, P Zhang, P Chi, Y Xiao, X M Xu, A M Zhang, X F Qiu, J X Wu, Y Yuan, Z N Wang, X J Qu, X Li, X Nie, M Yang, K L Cai, W K Zhang, Y Huang, Z Sun, Z G Hou, C Ma, F Z Cheng, K X Tao, T Zhang
BACKGROUND: Neoadjuvant short-course radiotherapy (SCRT) followed by CAPOX and camrelizumab (a PD-1 monoclonal antibody) has shown potential clinical activity for locally advanced rectal cancer (LARC) in a phase II trial. This study aimed to further confirm the efficacy and safety of SCRT followed by CAPOX and camrelizumab compared to long-course chemoradiotherapy (LCRT) followed by CAPOX alone as neoadjuvant treatment for LARC. PATIENTS AND METHODS: In this randomized, phase III trial, patients with T3-4/N+ rectal adenocarcinoma were randomly assigned (1:1) to receive SCRT or long-course chemoradiotherapy (LCRT), followed by 2 cycles of camrelizumab and CAPOX or CAPOX alone, respectively...
July 2, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38969011/esmo-clinical-practice-guideline-interim-update-on-new-targeted-therapies-in-the-first-line-and-at-relapse-of-chronic-lymphocytic-leukaemia
#7
JOURNAL ARTICLE
B Eichhorst, P Ghia, C U Niemann, A P Kater, M Gregor, M Hallek, M Jerkeman, C Buske
No abstract text is available yet for this article.
July 1, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38950679/intrapatient-variation-in-pd-l1-expression-and-tumor-mutational-burden-and-the-impact-on-outcomes-to-immune-checkpoint-inhibitor-therapy-in-patients-with-non-small-cell-lung-cancer
#8
JOURNAL ARTICLE
A Di Federico, S L Alden, J W Smithy, B Ricciuti, J V Alessi, X Wang, F Pecci, G Lamberti, M M Gandhi, V R Vaz, L F Spurr, L M Sholl, K L Pfaff, S J Rodig, Y Y Li, A D Cherniack, M Nishino, B E Johnson, M M Awad
BACKGROUND: PD-L1 tumor proportion score (TPS) and tumor mutational burden (TMB) are key predictive biomarkers for immune checkpoint inhibitors (ICI) efficacy in non-small cell lung cancer (NSCLC). Data on their variation across multiple samples are limited. METHODS: Patients with NSCLC and multiple PD-L1 TPS and/or TMB assessments were included. Clinicopathologic and genomic data were analyzed according to PD-L1 and TMB variation. RESULTS: In total, 402 PD-L1 sample pairs and 413 TMB sample pairs were included...
June 29, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38942080/amivantamab-plus-lazertinib-versus-osimertinib-in-first-line-egfr-mutant-advanced-non-small-cell-lung-cancer-with-biomarkers-of-high-risk-disease-a%C3%A2-secondary-analysis-from-mariposa
#9
JOURNAL ARTICLE
E Felip, B C Cho, V Gutiérrez, A Alip, B Besse, S Lu, A I Spira, N Girard, R Califano, S M Gadgeel, J C-H Yang, S Yamamoto, K Azuma, Y J Kim, K-H Lee, P Danchaivijitr, C G Ferreira, Y Cheng, M A N Sendur, G-C Chang, C-C Wang, K Prabhash, Y Shinno, D Stroyakovskiy, L Paz-Ares, J R Rodriguez-Cid, C Martin, M R G Campelo, H Hayashi, D Nguyen, P Tomasini, M Gottfried, C Dooms, A Passaro, M Schuler, A C Z Gelatti, S Owen, K Perdrizet, S-H I Ou, J C Curtin, J Zhang, M Gormley, T Sun, A Panchal, M Ennis, E Fennema, M Daksh, S Sethi, J M Bauml, S-H Lee
BACKGROUND: Amivantamab-lazertinib significantly prolonged progression-free survival (PFS) versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer [NSCLC; hazard ratio (HR) 0.70; P < 0.001], including those with a history of brain metastases (HR 0.69). Patients with TP53 co-mutations, detectable circulating tumor DNA (ctDNA), baseline liver metastases, and those without ctDNA clearance on treatment have poor prognoses. We evaluated outcomes in these high-risk subgroups...
June 26, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38908482/impact-of-hormone-receptor-status-and-tumor-subtypes-of-breast-cancer-in-young-brca-carriers
#10
JOURNAL ARTICLE
L Arecco, M Bruzzone, R Bas, H J Kim, A Di Meglio, R Bernstein-Molho, F S Hilbers, K Pogoda, E Carrasco, K Punie, J Bajpai, E Agostinetto, N Lopetegui-Lia, A H Partridge, K A Phillips, A Toss, C Rousset-Jablonski, G Curigliano, T Renaud, A Ferrari, S Paluch-Shimon, R Fruscio, W Cui, S M Wong, C Vernieri, F J Couch, M V Dieci, A Matikas, M Rozenblit, D Aguilar-Y Méndez, L De Marchis, F Puglisi, A Fabi, S L Graff, I Witzel, A Rodriguez, A Fontana, R Pesce, R Duchnowska, H L Pais, V Sini, E Sokolović, E de Azambuja, M Ceppi, E Blondeaux, M Lambertini
BACKGROUND: Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its impact on prognosis of young patients harboring BRCA pathogenic variant (PV). PATIENTS AND METHODS: This international, multicenter, retrospective cohort study included young patients (≤40 years) diagnosed with invasive breast cancer and harboring germline PV in BRCA genes. We investigated the impact of hormone receptor status on clinical behavior and outcomes of breast cancer...
June 20, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38906254/development-and-validation-of-ai-assisted-transcriptomic-signatures-to-personalize-adjuvant-chemotherapy-in-patients-with-pancreatic-ductal-adenocarcinoma
#11
JOURNAL ARTICLE
N Fraunhoffer, P Hammel, T Conroy, R Nicolle, J-B Bachet, A Harlé, V Rebours, A Turpin, M B Abdelghani, E Mitry, J Biagi, B Chanez, M Bigonnet, A Lopez, L Evesque, T Lecomte, E Assenat, O Bouché, D Renouf, A Lambert, L Monard, M Mauduit, J Cros, J Iovanna, N Dusetti
BACKGROUND: After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of gemcitabine-based regimens or the modified FOLFIRINOX regimen (mFFX). While mFFX has been shown to be more effective than gemcitabine-based regimens, it is also associated with higher toxicity. Current treatment decisions are based on patient performance status rather than on the molecular characteristics of the tumor. To address this gap, the goal of this study was to develop drug-specific transcriptomic signatures for personalized chemotherapy treatment...
June 19, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38866180/overall-survival-in-patients-with-endometrial-cancer-treated-with-dostarlimab-plus-carboplatin-paclitaxel-in-the-randomized-engot-en6-gog-3031-ruby-trial
#12
JOURNAL ARTICLE
M A Powell, L Bjørge, L Willmott, Z Novák, D Black, L Gilbert, S Sharma, G Valabrega, L M Landrum, M Gropp-Meier, A Stuckey, I Boere, M A Gold, Y Segev, S E Gill, C Gennigens, A Sebastianelli, M S Shahin, B Pothuri, B J Monk, J Buscema, R L Coleman, B M Slomovitz, K L Ring, T J Herzog, M Marco Balas, Ma Grimshaw, S Stevens, D W Lai, C McCourt, M R Mirza
BACKGROUND: Part 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin-paclitaxel compared with placebo plus carboplatin-paclitaxel in patients with primary advanced or recurrent endometrial cancer. At the first interim analysis, the trial met one of its dual-primary endpoints with statistically significant progression-free survival benefits in the mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) and overall populations. Overall survival (OS) results are reported from the second interim analysis...
June 10, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38857846/efficacy-and-safety-of-ramucirumab-plus-carboplatin-and-paclitaxel-in-untreated-metastatic-thymic-carcinoma-relevent-phase-ii-trial-nct03921671
#13
JOURNAL ARTICLE
C Proto, M Ganzinelli, S Manglaviti, M Imbimbo, G Galli, M Marabese, F Zollo, M F Alvisi, M Perrino, N Cordua, F Borea, F de Vincenzo, A Chella, S Cappelli, E Pardini, Z Ballatore, A Lucarelli, E Ambrosini, M Giuliano, E Pietroluongo, C Mulargiu, A Fabbri, A Prelaj, M Occhipinti, M Brambilla, L Mazzeo, T Beninato, R Vigorito, M Ruggirello, F G Greco, G Calareso, D Miliziano, E Rulli, I De Simone, V Torri, F G M de Braud, G Pasello, P De Placido, R Berardi, I Petrini, P Zucali, M C Garassino, G Lo Russo
BACKGROUND: Thymic carcinoma (TC) is a rare tumor with aggressive behavior. Chemotherapy with carboplatin plus paclitaxel represents the treatment of choice for advanced disease. Antiangiogenic drugs, including ramucirumab, have shown activity in previously treated patients. RELEVENT trial was designed to evaluate the activity and safety of ramucirumab plus chemotherapy as first-line treatment in advanced TC. PATIENTS AND METHODS: This phase II trial was conducted within the Italian TYME network...
June 8, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38852675/upfront-resection-versus-no-resection-of-the-primary-tumor-in-patients-with-synchronous-metastatic-colorectal-cancer-the-randomized-phase-3-cairo4-study-conducted-by-the-dutch-colorectal-cancer-group-and-the-danish-colorectal-cancer-group
#14
JOURNAL ARTICLE
D E W van der Kruijssen, S G Elias, P M van de Ven, K L van Rooijen, J 't Lam-Boer, L Mol, C J A Punt, D W Sommeijer, P J Tanis, J D Nielsen, M K Yilmaz, J M G H Van Riel, D K Wasowiz-Kemps, O J L Loosveld, G P van der Schelling, J W B de Groot, H L van Westreenen, H L Jakobsen, A L Fromm, P Hamberg, M Verseveld, C Jaensch, G I Liposits, P van Duijvendijk, J Oulad Hadj, J A B van der Hoeven, M Trajkovic, J H W de Wilt, M Koopman
BACKGROUND: Upfront primary tumor resection (PTR) has been associated with longer overall survival (OS) in patients with synchronous unresectable metastatic colorectal cancer (mCRC) in retrospective analyses. The aim of the CAIRO4 study was to investigate whether the addition of upfront PTR to systemic therapy resulted in a survival benefit in patients with synchronous mCRC without severe symptoms of their primary tumor. PATIENTS AND METHODS: This randomized phase 3 trial was conducted in 45 hospitals in The Netherlands and Denmark...
June 7, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38851588/reply-to-the-letter-to-the-editor-regarding-overcoming-barriers-in-biomarker-testing-j-%C3%A2-garc%C3%A3-a-foncillas-et-al
#15
LETTER
A Bayle, D Chaltiel, N Latino, E Rouleau, S Peters, M Galotti, G Bricalli, B Besse, R Giuliani, J Bonastre
No abstract text is available yet for this article.
June 6, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38838846/interpretation-of-long-term-survival-data-from-monarch-3-letter-to-the-editor-regarding-abemaciclib-plus-a-nonsteroidal-aromatase-inhibitor-as-initial-therapy-for-hr-her2-advanced-breast-cancer-final-overall-survival-results-of-monarch-3-by-m-p-goetz-et-al
#16
LETTER
Alexander D Sherry, Timothy A Lin, Zachary R McCaw, Ethan B Ludmir
No abstract text is available yet for this article.
June 3, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38838845/to-explain-the-unexplainable-in-monarch-3-overall-survival-the-restricted-mean-survival-time-letter-to-the-editor-regarding-abemaciclib-plus-a-nonsteroidal-aromatase-inhibitor-as-initial-therapy-for-hr-her2-advanced-breast-cancer-final-overall-survival-results
#17
LETTER
https://read.qxmd.com/read/38788900/renal-cell-carcinoma-esmo-clinical-practice-guideline-for-diagnosis-treatment-and-follow-up
#18
T Powles, L Albiges, A Bex, E Comperat, V Grünwald, R Kanesvaran, H Kitamura, R McKay, C Porta, G Procopio, M Schmidinger, C Suarez, J Teoh, G de Velasco, M Young, S Gillessen
No abstract text is available yet for this article.
May 20, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38834389/re-timing-of-radiotherapy-rt-after-radical-prostatectomy-rp-long-term-outcomes-in-the-radicals-rt-trial-nct00541047-by-c-c-parker-et-al-ann-oncol-2024-apr-5-s0923-7534-24-00105-4
#19
LETTER
E Mazzone, G Gandaglia, A Briganti, F Montorsi
No abstract text is available yet for this article.
May 16, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38761889/reply-to-letter-to-the-editor-regarding-timing-of-radiotherapy-rt-after-radical-prostatectomy-rp-long-term-outcomes-in-the-radicals-rt-trial-nct00541047-by-c-c-parker-et-al
#20
LETTER
C C Parker, C N Catton, N Clarke, P Meidahl, M Parmar, W Parulekar, M Sydes
No abstract text is available yet for this article.
May 15, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.